“Contravir announced that IND for CRV-431 (cyclophilin inhibitor) has been approved to move into the clinic for hepatitis B virus (HBV). Important to note is the design of the study, which in our view could potentially accelerate timelines for the HBV combination; TXL + CRV-431.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 10.1% and a 45.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and Actinium Pharmaceuticals.
ContraVir Pharmaceuticals Inc has an analyst consensus of Hold.
The company has a one-year high of $6.60 and a one-year low of $1.30. Currently, ContraVir Pharmaceuticals Inc has an average volume of 513.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. The company’s two of antiviral candidates for treating hepatitis B include phase 2a clinical candidate TXL, a novel, potent analog of the antiviral drug tenofovir that has demonstrated the potential for low, once a day dosing compared to viread and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a structure that increases its potency and selective index against hepatitis B virus. ContraVir Pharmaceuticals was founded on May 15, 2013 and is headquartered in Edison, NJ.